Blurbs

H.C. Wainwright Reiterates a Buy Rating on Gossamer Bio (GOSS)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Gossamer Bio (GOSSResearch Report) today and set a price target of $20.00. The company’s shares closed last Wednesday at $9.51.

According to TipRanks.com, Trucchio has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.1% and a 32.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gossamer Bio with a $14.25 average price target, implying an 87.0% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $14.30 and a one-year low of $5.64. Currently, Gossamer Bio has an average volume of 1.08M.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GOSS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Read More on GOSS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos